申请人:Lilly S.A.
公开号:US05015656A1
公开(公告)日:1991-05-14
A pharmaceutical compound of the formula ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 independently are hydrogen, hydroxy, halo, nitro, amino, C.sub.2-5 acylamino, C.sub.1-4 alkyl, --CHO, --CH.sub.2 OH, --CH.sub.2 OC.sub.1-4 alkyl, --COOH, --COC.sub.1-3 alkyl, --CH(OH)C.sub.1-3 alkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyloxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulphinyl, C.sub.1-4 alkylsulphonyl, N-substituted heterocyclyl, optionally substituted phenyl, optionally substituted phenylthio, optionally substituted phenylsulphinyl, optionally substituted phenylsulphonyl or optionally substituted phenylsulphonamido, or R.sup.1 and R.sup.2 together form a C.sub.3-5 alkylene bridge; provided that at least one of R.sup.2 and R.sup.3 is C.sub.1-4 alkoxy or C.sub.2-4 alkenyloxy; and X is (i) --(CH.sub.2).sub.n N(R.sup.4).sub.2 where each R.sup.4 independently is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or optionally substituted C.sub.6 H.sub.5 CH.sub.2 --, and n is 1, 2 or 3, or (ii) a 5- to 8-membered alicyclic group containing one or two nitrogen atoms and directly attached to the amido nitrogen or attached by a C.sub.1-3 alkylene chain; and salts and esters thereof.
化学式为##STR1##的药物化合物,其中R.sup.1,R.sup.2和R.sup.3独立地是氢,羟基,卤素,硝基,氨基,C.sub.2-5酰胺基,C.sub.1-4烷基,--CHO,--CH.sub.2 OH,--CH.sub.2 OC.sub.1-4烷基,--COOH,--COC.sub.1-3烷基,--CH(OH)C.sub.1-3烷基,C.sub.1-4烷氧基,C.sub.2-4烯基氧基,C.sub.1-4烷基硫基,C.sub.1-4烷基磺酰基,C.sub.1-4烷基磺基,N-取代的杂环基,可选择取代的苯基,可选择取代的苯基硫基,可选择取代的苯基磺酰基,可选择取代的苯基磺胺基,或者R.sup.1和R.sup.2共同形成一个C.sub.3-5烷基桥;前提是R.sup.2和R.sup.3中至少有一个是C.sub.1-4烷氧基或C.sub.2-4烯基氧基;X为(i)--(CH.sub.2).sub.n N(R.sup.4).sub.2,其中每个R.sup.4独立地是C.sub.1-4烷基,C.sub.2-4烯基或可选择取代的C.sub.6 H.sub.5 CH.sub.2 --,n为1, 2或3,或者(ii)一个含有一个或两个氮原子的5-到8-成员的脂环基,直接连接到酰胺氮或通过一个C.sub.1-3烷基链连接;以及其盐和酯。